US FDA News: FDA approves first PI3K inhibitor for breast cancer

FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant.
Read more: FDA approves first PI3K inhibitor for breast cancer